Characterized by sores on the skin that can become skin ulcers, they can appear in different parts of the body. This ailment ...

Visceral leishmaniasis (VL) is a severe infectious disease caused by a protozoan parasite: Leishmania donovani in East Africa and the Indian subcontinent and Leishmania infantum in Latin America ...

The London-based Alphabet-owned lab will work with the Drugs for Neglected Diseases initiative (DNDI) to treat Chagas disease ...

Carreira, J.C.A., Brazil, R.P. and da Silva, A.V.M. (2024) Leishmania in an Ecotourism Area in Rio de Janeiro: Still a ...

Are you searching for medications to treat 'Leishmaniasis'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Leishmaniasis. The page includes ...

Leishmaniasis has joined other diseases in spreading to new places as the warming planet opens up new populations to these diseases. According to the World Health Organization, there are between ...

An unusual case of Kala Azar has emerged in Lucknow's Triveni Nagar area, marking the first isolated instance of this disease ...

In an article published in PLOS Pathogens, they describe potential pharmaceutical targets for the treatment of visceral leishmaniasis. Existing therapeutic strategies are considered insufficiently ...

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today ...

Dr Deepak K Goyal from Panjab University’s zoology department placed third for his ongoing work on a kala-azar vaccine. Dr ...

Appili Therapeutics (APLIF) announced that the U.S. Food and Drug Administration has provided positive feedback regarding the development ...